We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+7.88%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$4B
AUM Growth
-$191M
Cap. Flow
-$236M
Cap. Flow %
-5.9%
Top 10 Hldgs %
48.84%
Holding
128
New
18
Increased
19
Reduced
24
Closed
26

Top Buys

Rank Stock Value
1
CAI
Caris Life Sciences
CAI
+$81.8M
2
UNH icon
UnitedHealth
UNH
+$51.6M
3
ROIV icon
Roivant Sciences
ROIV
+$30.1M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$23.2M
5
JBIO
Jade Biosciences
JBIO
+$18.1M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$97.6M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$76.6M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$56.9M
4
SWTX
SpringWorks Therapeutics
SWTX
+$41.9M
5
TMO icon
Thermo Fisher Scientific
TMO
+$34.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.99%
2 Miscellaneous 1.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KROS icon
51
Keros Therapeutics
KROS
$219M
$13.6M 0.34%
1,018,734
– –
RAPT
52
DELISTED
RAPT Therapeutics
RAPT
$13.1M 0.33%
1,641,906
-2
-0% -$15
FOLD
53
DELISTED
Amicus Therapeutics
FOLD
$13.1M 0.33%
2,285,400
– –
VIR icon
54
Vir Biotechnology
VIR
$1.83B
$12M 0.3%
2,380,715
+132,466
+6% +$710K
ABCL icon
55
AbCellera Biologics
ABCL
$3.68B
$11.5M 0.29%
3,344,568
-836,200
-20% -$2.08M
AKRO
56
DELISTED
Akero Therapeutics
AKRO
$11.3M 0.28%
211,300
+31,400
+17% +$1.43M
MLYS icon
57
Mineralys Therapeutics
MLYS
$2.26B
$10.3M 0.26%
+760,351
New +$11M
DYN icon
58
Dyne Therapeutics
DYN
$4.68B
$9.82M 0.25%
1,031,400
+16,789
+2% +$185K
CCCC icon
59
C4 Therapeutics
CCCC
$474M
$9.77M 0.24%
6,830,300
– –
ORIC icon
60
Oric Pharmaceuticals
ORIC
$1.37B
$9.13M 0.23%
899,281
+199,281
+28% +$1.34M
CPRX
61
DELISTED
Catalyst Pharmaceutical
CPRX
$9.05M 0.23%
+416,900
New +$9.84M
PRLD icon
62
Prelude Therapeutics
PRLD
$437M
$8.83M 0.22%
10,909,256
– –
CRBP icon
63
Corbus Pharmaceuticals
CRBP
$211M
$8.09M 0.2%
1,172,287
– –
ZLAB icon
64
Zai Lab
ZLAB
$2.93B
$8.08M 0.2%
+231,000
New +$7.59M
TARS icon
65
Tarsus Pharmaceuticals
TARS
$3.15B
$8.02M 0.2%
197,900
-455,843
-70% -$20.5M
WHWK
66
Whitehawk Therapeutics
WHWK
$263M
$7.79M 0.19%
4,166,000
– –
TYRA icon
67
Tyra Biosciences
TYRA
$1.49B
$7.7M 0.19%
804,603
-948,228
-54% -$9.01M
AZN icon
68
CALL
AstraZeneca
AZN
$252B
$6.99M 0.17%
+50,000
New +$7.01M
ACET icon
69
Adicet Bio
ACET
$84.8M
$6.98M 0.17%
715,446
– –
ITOS
70
DELISTED
iTeos Therapeutics
ITOS
$6.98M 0.17%
+700,000
New +$5.64M
PMVP icon
71
PMV Pharmaceuticals
PMVP
$65.2M
$6.86M 0.17%
6,475,291
– –
URGN icon
72
UroGen Pharma
URGN
$2.13B
$6.55M 0.16%
+478,400
New +$4.59M
ASND icon
73
Ascendis Pharma A/S
ASND
$16.3B
$5.94M 0.15%
+34,400
New +$5.6M
ALMS
74
Alumis Inc
ALMS
$2.9B
$5.78M 0.14%
+1,926,423
New +$9.1M
JBIO
75
Jade Biosciences
JBIO
$1.33B
$5.31M 0.13%
+531,163
New +$18.1M
1 2
3
4 5

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q2 2025 Portfolio in Review

As of Q2 2025, OrbiMed held 128 positions worth $4B, down 4.5% from $4.19B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

OrbiMed withdrew a net $236M in Q2 2025, closing 26 positions and reducing 24 holdings. Its most notable exit was Pfizer, an estimated $97.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

Against the trend, OrbiMed opened a new position in Caris Life Sciences worth $81.1M.

  • OrbiMed's largest Q2 2025 buy was Caris Life Sciences: 3,034,858 shares worth $81.1M.
  • OrbiMed added most to UnitedHealth in Q2 2025, an estimated $51.6M increase.
  • OrbiMed's biggest Q2 2025 reduction was Neurocrine Biosciences, cutting an estimated $56.9M.
  • OrbiMed fully exited Pfizer in Q2 2025, selling an estimated $97.6M.
  • OrbiMed's ten largest holdings make up 49% of its $4B portfolio in Q2 2025.
  • OrbiMed opened 18 new positions and closed 26 in Q2 2025.
  • OrbiMed's portfolio value fell 4.5% quarter-over-quarter to $4B.

Based on OrbiMed's 13F filing for Q2 2025, filed 14 Aug 2025.